Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.25
Bid: 40.00
Ask: 40.50
Change: 0.25 (0.63%)
Spread: 0.50 (1.25%)
Open: 40.00
High: 40.50
Low: 39.75
Prev. Close: 40.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Earnings, Trading Statements Calendar - Next 7 Days

Mon, 21st Sep 2020 16:08

Tuesday 22 September 
Judges Scientific PLCHalf Year Results
Close Brothers Group PLCFull Year Results
Ergomed PLCHalf Year Results
ASA International Group PLCHalf Year Results
Alliance Pharma PLCHalf Year Results
Frenkel Topping Group PLCHalf Year Results
Parity Group PLCHalf Year Results
Bluefield Solar Income Fund LtdFull Year Results
Longboat Energy PLCHalf Year Results
NAHL GroupHalf Year Results
Tremor International LtdHalf Year Results
Litigation Capital Management LtdFull Year Results
Cambridge Cognition Holdings PLCHalf Year Results
Personal Group Holdings PLCHalf Year Results
Inspecs Group PLCHalf Year Results
Oriole Resources PLCHalf Year Results
Learning Technologies Group PLCHalf Year Results
Kingfisher PLCHalf Year Results
AG Barr PLCHalf Year Results
Town Centre SecuritiesFull Year Results
Mortgage Advice Bureau (Holdings) PLCHalf Year Results
ADES International Holding PLCHalf Year Results
Wednesday 23 September 
PZ Cussons PLCFull Year Results
Equals Group PLCHalf Year Results
Warpaint London PLCHalf Year Results
ECSC Group PLCHalf Year Results
Xeros Technology Group PLCHalf Year Results
LoopUp Group PLCHalf Year Results
CloudCall Group PLCHalf Year Results
Ten Entertainment Group PLCHalf Year Results
Origin Enterprises PLCFull Year Results
Staffline Group PLCHalf Year Results
Thursday 24 September 
CVS Group PLCFull Year Results
Smiths Group PLCFull Year Results
Go-Ahead Group PLCFull Year Results
SIG PLCHalf Year Results
GYG PLCHalf Year Results
Mitchells & Butlers PLCTrading Update
Safestay PLCHalf Year Results
Ebiquity PLCHalf Year Results
DFS Furniture PLCFull Year Results
Faron Pharmaceuticals LtdHalf Year Results
Pendragon PLCHalf Year Results
RTW Venture Fund LtdHalf Year Results
Cineworld Group PLCHalf Year Results
Funding Circle Hodlings PLCHalf Year Results
Baillie Gifford Shin Nippon PLCHalf Year Results
United Utilities Group PLCTrading Statement
Friday 25 September 
Camellia PLCHalf Year Results
Pennon Group PLCTrading Statement
Monday 28 September 
Brand Architekts Group PLCFull Year Results
7digital Group PLCHalf Year Results
Ceres Power Holdings PLCFull Year Results
Avacta Group PLCHalf Year Results
Instem PLCHalf Year Results
Chesnara PLCHalf Year Results
Reach PLCHalf Year Results
  
Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
28 Jan 2020 11:57

Avacta Demonstrates Initial Proof Of Concept For Cancer Drug TMAC

Avacta Demonstrates Initial Proof Of Concept For Cancer Drug TMAC

Read more
23 Jan 2020 12:44

Affimer Unit Performance Helps Avacta Revenue Beat Market Forecasts

Affimer Unit Performance Helps Avacta Revenue Beat Market Forecasts

Read more
23 Jan 2020 10:28

Avacta doubles revenues thanks to LG Chem milestone payment

(Sharecast News) - Biotherapeutics development outfit Avacta doubled revenues in the 17-month period ended 31 December 2019 as it was boosted by an initial milestone payment from LG Chem.

Read more
21 Jan 2020 12:48

Avacta Group Hires Vectura Group CFO Fry As Non-Executive Director

Avacta Group Hires Vectura Group CFO Fry As Non-Executive Director

Read more
8 Jan 2020 15:27

Avacta Group enters joint venture with South Korea's Daewoong

(Sharecast News) - Biotherapeutics and reagents developer Avacta Group has agreed to establish a joint venture in South Korea with Daewoong Pharmaceutical, it announced on Wednesday, and to enter into a collaboration and license agreement for the joint venture to develop the next generation of cell and gene therapies, incorporating its 'Affimer' proteins to enhance the immune-modulatory effects.

Read more
8 Jan 2020 10:40

Avacta To Establish Gene Therapy Joint Venture With Daewoong Pharma

Avacta To Establish Gene Therapy Joint Venture With Daewoong Pharma

Read more
13 Nov 2019 13:51

Avacta Expands Contract With LG Chem After First Programme Completes

Avacta Expands Contract With LG Chem After First Programme Completes

Read more
13 Nov 2019 11:50

Avacta Group reports solid progress in partnership with LG Chem

(Sharecast News) - Biotherapeutics developer Avacta Group updated the market on the 'Affimer' therapeutics development partnership and license agreement with LG Chem Life Sciences, part of the South Korean LG Group, to develop Affimer therapeutics in several disease areas on Wednesday.

Read more
4 Nov 2019 18:15

Avacta Non-Executive Sam Williams Steps Down After General Meeting

Avacta Non-Executive Sam Williams Steps Down After General Meeting

Read more
18 Oct 2019 13:20

Avacta Plans GBP9 Million Fundraise; Loss Widens On Research Costs

Avacta Plans GBP9 Million Fundraise; Loss Widens On Research Costs

Read more
10 Oct 2019 11:24

Avacta Teams With ADC Therapeutics To Develop Affimer-Drug Conjugates

Avacta Teams With ADC Therapeutics To Develop Affimer-Drug Conjugates

Read more
10 Oct 2019 08:39

Avacta inks collaboration deal with ADC Therapeutics

(Sharecast News) - Biotechnology company Avacta Group has entered a collaboration and option agreement with ADC Therapeutics, which it described as a Switzerland-based clinical-stage oncology-focused biotechnology company pioneering the development of "highly potent and targeted" antibody-drug conjugates for patients suffering from haematological malignancies and solid tumours.

Read more
20 Jun 2019 10:28

Avacta partners with Selexis ahead of first-in-human trials

(Sharecast News) - Avacta Group announced on Thursday that it has partnered with life sciences company Selexis to develop the Chinese hamster ovary (CHO) cell line, which will be used to manufacture Avacta's first 'Affimer' clinical candidate for first-time-in-human clinical trials.

Read more
10 Jun 2019 10:51

Avacta Selects Candidate For First Human Trials Of Affimer Platform

LONDON (Alliance News) - Avacta Group PLC on Monday said it has selected a clinical development candidate AVA004 for first-time-in-human clinical trials of its Affimer platform.Affimer an a

Read more
3 Jun 2019 10:20

Avacta To Submit Application For TMAC Linker Testing In Tumours Study

LONDON (Alliance News) - Avacta Group PLC on Monday said it is planning to submit an application to test its TMAC linker in patients with selected solid tumours in early 2020.The company, a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.